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Abstract 
Herpes labialis, commonly known as cold sores, is an infection of the mouth and surrounding area. Antiviral therapy can be used to 
block viral replication, which shortens the duration of symptoms, facilitates resolution of lesions, and lessens the risk of spreading the 
virus. Increasing access to antivirals targeted against herpes labialis by allowing assessment and prescribing by a pharmacist may 
decrease time to treatment for HSV-1, and improve patient satisfaction. Experience from Canada, Australia, New Zealand and the 
United States demonstrate that pharmacist management of cold sores has a safe track record and may be considered by other 
jurisdictions. 
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Background 
Herpes labialis, commonly known as cold sores, is an infection 
of the mouth and surrounding area caused primarily by herpes 
simplex virus type 1 (HSV-1), and less commonly by herpes 
simplex virus type 2 (HSV-2).1 HSV-1 is a highly contagious virus 
that can be spread through direct or indirect contact with 
infected individuals.  In the United States, there are 
approximately 500,000 primary infections with HSV-1 each 
year.2 It is estimated that by age 50, about 90% of adults have 
been exposed to HSV-1.3  Following the primary 
infection/episode with HSV-1 the virus is retained in the body 
and approximately 1/3 of all infected individuals experience a 
relapse during their lifetime.4 Prior to experiencing a recurrent 
episode, prodromal symptoms (e.g., tingling, itching, burning) 
typically precede the formation of lesions.1Infections are rarely 
serious and are typically self-limiting among 
immunocompetent hosts. Most lesions completely resolve 
within 2-4 weeks.1  
 
In the United States, the Food and Drug Administration (FDA) 
has approved several over-the-counter products as well as 
prescription-only antivirals for the episodic treatment of 
recurrent cold sores, both in topical and oral forms.1 Topical 
antiviral agents include penciclovir cream and acyclovir cream, 
while oral agents include acyclovir, famcyclovir, and 
valacyclovir. Antiviral therapy can be used to block viral 
replication, which shortens the duration of symptoms, 
facilitates resolution of lesions, and lessens the risk of spreading 
the virus.5 In order to realize maximum benefit, antiviral 
therapy is to be initiated as soon as possible following the onset 
of symptoms. Studies have demonstrated that use of antivirals 
can shorten the duration of and decrease pain associated with 
lesions. Some evidence suggests that oral medications maybe 
more effective than the topical agents.6  
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Oral antivirals can also be used prophylactically among those 
who experience frequent relapses. Topical agents are 
ineffective for prophylaxis since they do not penetrate to the 
site of reactivation.7 
 
Although topical and systemic antivirals have been proven 
effective against HSV-1 and well tolerated, they are available 
only with a prescription in the United States.  As a result, many 
patients do not have access to these medications in a 
timeframe that would optimize their benefits.  Increasing 
access to antivirals targeted against herpes labialis by allowing 
assessment and prescribing by a pharmacist may decrease time 
to treatment for HSV-1, relieve congestion within the medical 
system, and improve patient satisfaction with their medical 
care. These benefits have been demonstrated for other acute, 
self-limiting conditions, such as influenza and streptococcal 
pharyngitis.8 This paper aims to summarize literature with 
respect to pharmacy-based assessment and management of 
cold sores to help regulators explore pharmacist prescriptive 
authority for oral antivirals. 
 
Considerations for Over-the-Counter or Pharmacist-
Prescribed Antiviral Therapy 
Reclassification of antivirals is not a new idea. In 1994, the U.S. 
Food and Drug Administration (FDA) considered switching oral 
acyclovir to an over-the-counter product for genital herpes.9 A 
consensus panel met to discuss considerations for such a switch 
for episodic treatment of genital herpes. With respect to viral 
resistance, there were mixed opinions on what the outcome of 
over-the-counter (OTC) acyclovir would be, though the panel 
acknowledged “almost all acyclovir resistance has been seen in 
immunocompromised individuals.”9 Given the safe track record 
of acyclovir in over 30 million people at the time, the panel 
concluded “the availability of OTC acyclovir would probably not 
be associated with significant safety problems.” The biggest 
concern of the panel was that such a switch could set a 
precedent that would encourage other manufacturers of 
antimicrobials to seek OTC status which could drive the 
development of resistance, and as a result the panel 
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recommended against OTC status for oral acyclovir for the 
treatment of genital herpes.9                                                                                      
 
Another report was published in 2012, this time evaluating the 
risks and benefits of moving antiviral therapies from 
prescription-only to a pharmacist-prescribed class of 
medications.5 The panel noted that the diagnoses of cold sores 
is based on the patient’s history as well as signs and symptoms, 
and that laboratory confirmation is rarely needed. Given this, 
the panel noted that a pharmacist-prescribed antiviral move 
should “save the patient’s time and offer greater convenience” 
and afford “early administration of the drug as first symptoms 
occur during the brief window of therapeutic opportunity.” The 
panel reviewed the potential impact on four domains: 1) 
efficacy; 2) safety; 3) resistance; and 4) monitoring.5 
 
With respect to efficacy, the panel noted that the increased 
accessibility of oral antiviral mediations in a pharmacist-
prescribed class might result in earlier initiation, resulting in 
more effective treatment and possibly prevent lesion 
development. The panel did not feel safety was a major 
concern, given that oral antivirals are “generally well tolerated 
and associated with minimal adverse events in patients.” 
Similar to the previous panel, resistance was a concern, though 
it was noted that HSV-1 resistance remains low (<0.5%) in 
immunocompetent patients, and thus the panel concluded that 
the development of resistance is unlikely if used episodically in 
immunocompetent hosts. For monitoring, the panel suggested 
that monitoring systems be established to ensure that patients 
did not self-treat genital herpes with oral antivirals, and that 
there were systems in place for monitoring patient safety and 
appropriateness of labeling.5 
 
In addition, three surveys were identified in which Canadian 
pharmacists or physicians expressed opinions on pharmacist-
prescribed cold sore medications. In 2014, the Ontario 
Pharmacists Association conducted a survey of more than 200 
of its members.10 Of note, 91.4% of respondents supported 
pharmacist prescriptive authority for minor ailments and 73.4% 
reported being prepared for this expanded authority. With 
respect to which specific conditions that pharmacists should be 
able to prescribe for, only four conditions were selected by 
more than 90% of respondents: allergic rhinitis (93.6%), insect 
bites (93.6%), cold sores (92.9%), and canker sores (90.7%).10 
 
A second survey was conducted of 268 Saskatchewan 
pharmacists in 2015, of whom 89.5% had already prescribed 
medication for at least one minor ailment.11 The province 
currently allows pharmacists to prescribe for up to 17 
conditions, and pharmacists were surveyed on which 
conditions they felt were of least concern for patient safety. 
Cold sores were rated as the least concern by a large margin.11 
A third study was conducted of 289 Saskatchewan physicians.12 
Physicians also selected cold sores as the condition of lowest 
concern to patient safety with respect to pharmacist 
prescribing. 
Select Models of Pharmacist Prescriptive Authority for Cold 
Sores 
Canada 
Pharmacists in some Canadian provinces have had the legal 
authority to independently prescribe antivirals for cold sores 
since at least 2007.13 In 2011, Nova Scotia and Saskatchewan 
created lists of “minor ailments” that pharmacists are 
authorized to independently prescribe for; these lists include 
cold sores, mild acne, allergic rhinitis, and thrush, among other 
ailments.13 As of 2016, six provinces explicitly include cold sores 
as part of their minor ailments prescribing authority (Alberta, 
New Brunswick, Newfoundland, Nova Scotia, Prince Edward 
Island, Quebec, and Saskatchewan).13-15 This authority is 
classified as an autonomous, independent prescribing model.16 
 
Studies have consistently found that cold sores are the most 
commonly prescribed for condition on minor ailments lists. 
From February 1, 2012 to December 31, 2013, cold sores 
accounted for 4,877 billings (49.4%) with a total of $87,768.01 
CAD ($17.99/per episode CAD) to Saskatchewan pharmacies.17 
An additional 4,453 prescribing encounters (45% of total 
encounters) were reported from January 2014 to December 
2014 in Saskatchewan.13 Ninety Saskatchewan pharmacies 
participated in a study from September 2012 to August 2013 to 
evaluate patient experiences with pharmacists’ prescribing for 
minor ailments.18 Cold sores were the most frequently treated 
minor ailment (34.4%, n=43) in this study. While not specific to 
cold sores, patients seeking treatment at the pharmacy most 
commonly reported symptoms had been present just one day 
before visiting the pharmacy (30.4%), and most patients 
(71.5%) asked the pharmacist for help as opposed to being 
offered help. In addition, patients reported that had they not 
sought pharmacist assessment, they would have purchased an 
OTC medication (43.2%) or have gone to the doctor (35.2%), 
suggesting patients would either receive suboptimal therapy or 
misallocate resources by seeking care at a more expensive 
facility.18 
 
A pilot study in Nova Scotia was conducted in 27 pharmacies 
from May 21, 2013 to August 16, 2013 to evaluate pharmacists 
prescribing for minor ailments.19 Pharmacies were reimbursed 
$22.50 per patient treated for a minor ailment. A total of 1,002 
had a minor ailment treated during the study period with cold 
sores accounting for the most frequently treated ailment (17%, 
n=167). While not specific to cold sores, 93% of the patient 
assessments yielded a prescription, 96% of patients indicated 
the service was beneficial or very beneficial, and 89% of 
patients reported that their concern was satisfactorily resolved. 
Moreover, 96% of patients noted they were “able to access 
health care sooner as a result of the minor ailment service.”19 
No negative patient health outcomes were reported relative to 
cold sore management. 
 
Consistent with the perception that cold sores were among the 
lowest-risk conditions for pharmacists to treat, a survey of 
Saskatchewan pharmacists found that very few patients 
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presenting with cold sores needed a medical referral, with 30% 
of pharmacists saying they never facilitated a referral for this 
condition, and 54% estimating only a 1-10% referral rate.13 
 
Two studies on patient experiences with pharmacy-based 
minor ailment services include open-ended feedback from 
patients. Comments relevant to prescribing for cold sores 
follow: 
 “It is great to know that I can come in to the pharmacy to 
get something for my cold sore rather than waiting at the 
doctor’s office.”17 
 “I am very pleased with this service. In the past, I treated 
cold sores with Abreva or Lipactin, which cost about $15-
20. Valtrex covered under my health benefits cost $3 and 
it caused my cold sore to be much less disruptive and it 
was gone in 2 days.”20 
 
Australia and New Zealand 
In 2010, New Zealand re-classified famcyclovir to a 
“pharmacist-only” medication (POM).5,21 This move was soon 
followed by Australia.22 In New Zealand and Australia, 
medications that are classified as POM fall in an area between 
OTC and prescription-only drugs. While a POM can be 
purchased without a physician’s prescription, the sale must be 
completed by a pharmacist and the pharmacist typically 
performs an assessment to ensure appropriateness of the 
medication prior to sale.23 Part of the rationale for the switch in 
New Zealand was the belief that “compliance for a single tablet 
dose should be higher than a cream used multiple times 
daily.”22 No published information was found on the outcomes 
associated with POM famcyclovir in either county. 
 
United States 
Florida maintains a formulary of drugs that a pharmacist may 
dispense “within their professional judgment.”24 Products are 
added to the formulary by a subset of members of the boards 
of pharmacy, medicine, and osteopathic medicine. Topical 
antivirals – but not oral formulations -- are a drug category 
included in the formulary, with penciclovir and acyclovir 
ointment specifically listed. Acyclovir ointment is limited to 
treatment of herpes simplex infections of the lip, though no 
such limitation is listed for penciclovir.24 While no published 
studies on the uptake of topical antivirals in Florida were found, 
these drugs have remained on the formulary since 1999 and 
were not removed in the 2007 update to the regulation, 
suggesting no significant safety issues have emerged. Florida 
pharmacists have, in general, not utilized this prescriptive 
authority to a large extent.25 Reasons for limited uptake include 
workflow and payment considerations.25 
 
Idaho was the first state to allow pharmacists to independently 
prescribe any FDA-approved prescription for cold sores, 
including oral antivirals.26 The law, which took effect on July 1, 
2018, allows a pharmacist to prescribe either oral or topical 
antivirals for cold sores. The law initially required pharmacists 
to use a patient assessment protocol that specifies inclusion, 
exclusion, and medical referral criteria based on evidence-
based research to ensure patients are appropriately triaged. 
Further, the law requires pharmacists to notify the patient’s 
primary care provider of any prescription written within five 
business days to ensure care is not fragmented by pharmacist 
prescribing.26 One Idaho regional pharmacy chain noted that 
cold sores rank among the most sought-after service on Idaho’s 
prescribing list; patients generally pay cash for a clinical 
consultation and the antiviral (when appropriate) is billed to the 
patient’s insurer.27 
 
Discussion 
Oral antivirals for cold sores are more effective than OTC 
medications and have a strong safety profile. These products 
are routinely prescribed in Canada by pharmacists and are 
among the most common minor ailments for which patients 
seek treatment from a pharmacist. When tasked with exploring 
moving acyclovir to an OTC status or pharmacist-prescribed 
status, an expert consensus panel did not have concerns over 
patient safety or emergence of antiviral resistance when used 
in immunocompetent patients.  
 
In general, protocols are leveraged to help pharmacists identify 
which patients may be safely treated in a pharmacy versus 
those who may need to be seen by another medical 
professional. Pharmacists have a history of successfully using 
protocols to identify appropriate candidates for treatment 
while referring patients when necessary because of the 
presence of certain high-risk factors for conditions such as 
influenza, strep throat, and uncomplicated urinary tract 
infections.8,28-29 Three such treatment protocols were found, 
with parameters for treatment and referral varying by 
jurisdiction.30-32 In addition, a standardized form is available for 
the pharmacist to perform the assessment for referral criteria, 
and to document the prescribing record.33-34 
 
A summary of the referral criteria from these protocols is 
provided in Table 1. The available protocols for the treatment 
of cold sores are generally consistent in suggesting referral if 
patients are immunocompromised, if systemic symptoms are 
present, or if lesions appear on areas other than the mouth. A 
patient assessment protocol is a core element that can ensure 
pharmacists provide safe and effective care in accordance with 
evidence-based care. Further, the protocol can provide the 
safeguards Cunningham and colleagues described, namely 
guarding against the misuse of such antivirals for self-treatment 
of genital herpes and having a pharmacist in place to monitor 
safety as part of the routine follow-up care process.5  
 
Conclusion 
With the appropriate safeguards in place, pharmacists can 
safely assess and treat patients who have cold sores with oral 
antivirals as has been the case in several jurisdictions. 
Regulatory bodies in the United States may consider pharmacist 
independent prescriptive authority for oral antivirals for the 
treatment of cold sores as a means to improve access to patient 
care.  
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Table 1. Referral Criteria for Pharmacy-Managed Cold Sores 
 
Referral Criteria Saskatchewan30 Australia31 Idaho32 
Patient Age Not addressed Refer if <18 years 
 
Refer if <6 years 
 
Patient Immune Status Refer if immunocompromised Refer if immunocompromised 
 
Refer if immunocompromised 
 
Systemic Symptoms 
Refer if “fever, swollen glands 
or other systemic symptoms” 
 
Refer if “Systemic symptoms present” 
Refer if “Symptoms of systemic 
illness are present (fever, swollen 
glands, malaise)” 
Lesion Duration 
Refer if present >14 days or if 
“lesion does not completely 
heal between episodes” 
Refer if present >7 days Can only treat if lesion <48 hours 
Lesion Location 
Refer if “lesion on or around 
nose” 
Refer if “lesions on other parts of the 
body” 
Refer if “lesion appears on area 
other than around the mouth and 
lips” 
Lesion Features 
Refer if “lesion excessively 
red, swollen, or contains pus” 
Refer if “signs of bacterial skin 
infection” or if there is “Painful mouth 
ulceration with poor oral intake” 
Refer if “lesion appears excessively 
red, swollen, or contains pus” 
Frequency Refer if >6 episodes per year Refer if >3 episodes per year 
 
Refer if >6 episodes in 12 months 
 
Follow-up 
Follow-up at day 7 and refer if 
no signs of response 
Follow-up at day 7 and refer if no 
signs of response 
Follow-up at day 7 and refer if 
lesions spread or persist without 
improvement 
 
 
